YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

AbbVie Inc. ABBV | NYSE

$260.03 -$1.56 | -0.60%

SIGNAL:

Signal available — unlock to view

|2026-09-23 |F&G 52 |RSI 48.7

Add to favoritesFavorite

Company Overview:

Market Cap: $459.91B

Trailing PE: 73.5x

FWD PE *: 17.1x

Payout Ratio (TTM): 189.6%

52-Week Range: $190.75 - $269.39

* Forward PE is based on street estimates.

10 Year ABBV Performance Metrics:

Total Return (with DRIP): 498.4% (19.59% CAGR)

Total Return (no DRIP): 383.5% (17.07% CAGR)

Share Price: 311.2% (15.19% CAGR)

Yield on Cost (with DRIP): 15.93%

Total Invested: $10,000

Total Value (with DRIP): $59,842

Total Return $ (with DRIP): $49,842

Dividend Increase: 170.3% (10.73% CAGR)

Dividend Yield (FWD): 2.66% ($6.92)

ABBV 10-yr Total Return ($10K invested)

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ABBV Share Price

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

ABBV Price CAGR:1Y: 6.40%2Y: 14.90%5Y: 18.97%10Y: 15.22%

ABBV Dividend Charts

ABBV - Dividends

ABBV Dividend CAGR:1Y: 5.49%2Y: 5.65%5Y: 5.88%10Y: 11.74%

ABBV - Dividend Payout Ratio

ABBV Dividend Payout Ratio CAGR:1Y: -72.61%2Y: -34.94%5Y: -22.38%10Y: 3.97%

ABBV - Dividend to Free Cash Flow Ratio

ABBV Dividend to FCF Ratio CAGR:1Y: 65.46%2Y: -14.69%5Y: 14.91%10Y: 6.63%

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

ABBV Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ABBV - Revenue

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - Earnings Per Share (EPS)

ABBV EPS CAGR:1Y: 283.02%2Y: 61.32%5Y: 37.04%10Y: 7.55%

ABBV - Net Income

🔓 See the full chart40% off right now · 7-day free trial

ABBV Net Income CAGR:1Y: 285.50%2Y: 62.46%5Y: 36.40%10Y: 8.43%

ABBV - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

ABBV EBITDA CAGR:1Y: 65.70%2Y: 19.95%5Y: 1.62%10Y: 10.40%

ABBV - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

ABBV Free Cash Flow CAGR:1Y: -36.24%2Y: 23.85%5Y: -7.88%10Y: 5.71%

ABBV - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

ABBV Free Cash Flow / Share CAGR:1Y: -24.18%2Y: 34.95%5Y: -4.67%10Y: 6.62%

ABBV - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

ABBV Operating Income CAGR:1Y: 37.37%2Y: 29.68%5Y: 8.65%10Y: 10.91%

ABBV - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

ABBV Gross Profit CAGR:1Y: 14.64%2Y: 11.25%5Y: 6.12%10Y: 9.67%

ABBV - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

ABBV Shares Outstanding CAGR:1Y: -0.06%2Y: 0.00%5Y: -0.06%10Y: 0.82%

ABBV - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

ABBV Share Buybacks CAGR:1Y: -25.00%2Y: 0.00%5Y: -2.09%10Y: -45.37%

ABBV - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ABBV Stock-Based Comp CAGR:1Y: -7.26%2Y: -12.74%5Y: 0.87%10Y: 8.86%

ABBV - Expenses

🔓 See the full chart40% off right now · 7-day free trial

ABBV Expenses CAGR:1Y: -1.49%2Y: 4.86%5Y: 6.33%10Y: 7.30%

ABBV - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

ABBV - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ABBV - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

ABBV - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ABBV - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ABBV - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

ABBV - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

ABBV Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ABBV - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ABBV Actual Revenue CAGR:1Y: 10.16%2Y: 8.39%5Y: 4.01%10Y: 10.17%

ABBV - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ABBV Actual EPS CAGR:1Y: 283.02%2Y: 61.32%5Y: 37.04%10Y: 7.55%

ABBV - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ABBV Actual Net Income CAGR:1Y: 285.50%2Y: 62.46%5Y: 36.40%10Y: 8.43%

ABBV - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ABBV Actual EBITDA CAGR:1Y: 65.70%2Y: 19.95%5Y: 1.62%10Y: 10.40%

Ratios, Profit Margins & Return on Capital:

ABBV - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ABBV Net Profit Margin CAGR:1Y: 249.84%2Y: 49.87%5Y: 31.11%10Y: -1.58%

ABBV - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ABBV Gross Profit Margin CAGR:1Y: 4.07%2Y: -6.20%5Y: 2.03%10Y: -0.45%

ABBV - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

ABBV Price to Earnings CAGR:1Y: -64.78%2Y: -25.12%5Y: -13.86%10Y: 7.04%

ABBV - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

ABBV Price To Sales Ratio CAGR:1Y: 22.99%2Y: 12.19%5Y: 12.94%10Y: 5.35%

ABBV - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

ABBV Return on Capital Employed CAGR:1Y: 36.94%2Y: 31.19%5Y: 13.07%10Y: 5.26%

ABBV - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

ABBV Return on Invested Capital CAGR:1Y: 89.08%2Y: 53.32%5Y: 11.48%10Y: 2.39%

ABBV Dividends Info:

Annual Dividend: $6.92

Forward Yield: 2.66%

Ex-Dividend Date: 2026-10-15

Lifetime Dividends / Share: $59.15

ABBV Dividend History: Dates, Payments & Yield list

Below is a schedule of all ABBV dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
10/15/2026	11/16/2026	$1.730	2.62%	0%	$0.00
07/15/2026	07/17/2026	$1.730	2.83%	2.72%	$254.49
04/15/2026	04/17/2026	$1.730	3.32%	3.32%	$208.38
01/16/2026	01/19/2026	$1.730	3.23%	2.97%	$232.86
10/15/2025	10/17/2025	$1.640	2.9%	2.86%	$229.57
07/15/2025	07/17/2025	$1.640	3.52%	3.43%	$191.40
04/15/2025	04/17/2025	$1.640	3.71%	3.79%	$172.99
01/15/2025	01/17/2025	$1.640	3.83%	3.82%	$171.54
10/15/2024	10/17/2024	$1.550	3.23%	3.29%	$188.57
07/15/2024	07/17/2024	$1.550	3.69%	3.54%	$175.27
04/12/2024	04/15/2024	$1.550	3.82%	3.83%	$161.67
01/12/2024	01/15/2024	$1.550	3.82%	3.51%	$176.59
10/12/2023	10/16/2023	$1.480	3.99%	4.02%	$147.23
07/13/2023	07/17/2023	$1.480	4.43%	4.39%	$134.83
04/13/2023	04/17/2023	$1.480	3.64%	3.67%	$161.18
01/12/2023	01/16/2023	$1.480	3.89%	3.92%	$151.06
10/13/2022	11/15/2022	$1.410	3.95%	3.69%	$153.04
07/14/2022	08/15/2022	$1.410	3.75%	3.96%	$142.29
04/13/2022	05/16/2022	$1.410	3.55%	3.63%	$155.47
01/13/2022	02/15/2022	$1.410	4.22%	3.9%	$144.76
10/14/2021	11/15/2021	$1.300	4.77%	4.45%	$116.84
07/14/2021	08/16/2021	$1.300	4.43%	4.39%	$118.41
04/14/2021	05/14/2021	$1.300	4.91%	4.47%	$116.43
01/14/2021	02/16/2021	$1.300	4.66%	4.99%	$104.20
10/14/2020	11/16/2020	$1.180	5.48%	4.8%	$98.36
07/14/2020	08/14/2020	$1.180	4.77%	4.96%	$95.07
04/14/2020	05/15/2020	$1.180	5.75%	5.2%	$90.71
01/14/2020	02/14/2020	$1.180	5.35%	5.02%	$94.05
10/11/2019	11/15/2019	$1.070	5.81%	4.83%	$88.63
07/12/2019	08/15/2019	$1.070	6.09%	6.8%	$62.98
04/12/2019	05/15/2019	$1.070	5.3%	5.43%	$78.78
01/14/2019	02/15/2019	$1.070	5.05%	5.29%	$80.85
10/12/2018	11/15/2018	$0.960	4.23%	4.26%	$90.14
07/12/2018	08/15/2018	$0.960	4.02%	3.94%	$97.45
04/12/2018	05/15/2018	$0.960	4.17%	3.69%	$104.18
01/11/2018	02/15/2018	$0.710	2.86%	2.47%	$114.90
10/12/2017	11/15/2017	$0.640	2.8%	2.73%	$93.76
07/12/2017	08/15/2017	$0.640	3.56%	3.64%	$70.34
04/11/2017	05/15/2017	$0.640	3.99%	3.84%	$66.67
01/11/2017	02/15/2017	$0.640	4.19%	4.15%	$61.65
10/12/2016	11/15/2016	$0.570	3.72%	3.63%	$62.87
07/13/2016	08/15/2016	$0.570	3.52%	3.38%	$67.39
04/13/2016	05/16/2016	$0.570	3.86%	3.65%	$62.45
01/13/2016	02/16/2016	$0.570	4.45%	4.26%	$53.51
10/13/2015	11/16/2015	$0.510	3.79%	3.4%	$60.01
07/13/2015	08/14/2015	$0.510	2.93%	2.97%	$68.65
04/13/2015	05/15/2015	$0.510	3.33%	3.09%	$65.99
01/13/2015	02/13/2015	$0.490	3.09%	3.38%	$58.05
10/10/2014	11/17/2014	$0.420	3.06%	2.58%	$65.04
07/11/2014	08/15/2014	$0.420	3.06%	3.12%	$53.90
04/11/2014	05/15/2014	$0.420	3.62%	3.19%	$52.69
01/13/2014	02/14/2014	$0.400	3.21%	3.15%	$50.73
10/10/2013	11/15/2013	$0.400	3.5%	3.3%	$48.44
07/11/2013	08/15/2013	$0.400	3.65%	3.7%	$43.21
04/11/2013	05/15/2013	$0.400	3.7%	3.48%	$46.03
01/11/2013	02/15/2013	$0.400	4.73%	4.26%	$37.58

Projected Future Returns & Dividends for ABBV

Based on past 10-year performance, here are ABBV growth metrics:

Share price CAGR of +15.22%
Dividend CAGR of +11.74%

Using ABBV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ABBV (DRIP)	ABBV - No DRIP
Current Price	$260.03	$260.03
Start Shares	38.46	38.46
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	48.50	38.46
Dividends Payment	$5.25	$5.25
Annual Dividends	$1,019	$808
Yield on cost	10.19%	8.08%
Share Price	$1,072.07	$1,072.07
Total Dividends	$5,315	$4,612
Final Value	$51,998	$45,841

Estimated Future Value + Dividends - ABBV

NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is traded on NYSE stock exchange.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

ABBV website: https://www.abbvie.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — ABBV

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $260.03

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own ABBV? See every dividend it's paid you

Add your ABBV shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every ABBV dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

Add ABBV free →

Free plan · up to 5 holdings